Archive · 26 Jan 2026
Ozempic Approval Sparks Obesity Debate in India
A new medicine called Ozempic has been approved in India to help people with diabetes.
This has started a big discussion about obesity, which is when people are very overweight.
In India, almost 1 in 4 adults is overweight, and this number is growing.
Around the world, the number of overweight adults has doubled in the last 30 years, and for teenagers, it has quadrupled.
There are now 35 million overweight children under five and 400 million overweight children between five and 19 years old.
Hospitals in India are offering services to help people lose weight and stay healthy.
This shows that obesity is a serious problem that needs more attention and discussion.
Ozempic approved in India for diabetes treatment, sparking obesity debate.
India's anti-obesity pharma market has grown nearly five times in the last half-decade.
Obesity prevalence among adults has doubled globally in the last 30 years.
Nearly 1 in 4 Indian adults is overweight according to NFHS 5 data.
Global obesity crisis includes 35 million overweight under-five children and 400 million overweight 5-19 year-olds.
- Who
- Indian adults and adolescents, global population
- What
- Approval of Ozempic for diabetes treatment and obesity debate
- When
- Recent approval, obesity trends over last 30 years
- Where
- India and globally
- Why
- Growing obesity epidemic and wellness culture
- Drug Approved
- Ozempic
- Market Growth
- Five times in last half-decade
- Adult Obesity Rate
- Nearly 1 in 4
- Global Adult Obesity Increase
- Doubled in last 30 years
- Global Adolescent Obesity Increase
- Quadrupled in last 30 years
- Overweight Under-Five Children
- 35 million
- Overweight 5-19 Year-Olds
- 400 million